Logo, Whitney Medical

1117 Route 46 E
Clifton, NJ 07013

Cannabis and Compassionate Care Programs

Oct 10
Everyone should have fair access to medical cannabis and compassionate care programs can help with this.  Cannabis and Compassionate Care Programs
Written by Dawna Lemoine

Everyone should have fair access to medical cannabis. The costs of obtaining medical cannabis can be hard to bear and with legalization taking place it can make it even more difficult to acquire affordable cannabis. As the acceptance of cannabis grows across the states so does the demand, which in turn can cause an increase in prices.

When you're trying to medicate that is the last thing on your mind, it is difficult to make life choices because of financial issues.
Thankfully there are some programs out there that can help ease the financial burden a little. But first, let's take a look at how much is spent on average by a cannabis patient to fully understand the importance of Compassionate Care programs.

How Much do Cannabis Patients Spend a Month? 

A study was conducted in 2016 on how much medical cannabis users spend a month.  On average people spend between $50-150 a month. The ages are between 18-65+ with a mean average of 51%. That is a lot of money to spend on something you are dependent on to help relieve your ailments.
Source: statista.com

What is a Cannabis Compassionate Care Program?

Various organizations across the states have recognized the issue that citizens may not be able to afford medical cannabis. Unfortunately licensed producers and the government holds the monopoly on the pricing of cannabis. So people that are in desperate need of cannabis are at their mercy. Thankfully there are various organizations coming together to support these people in need. They provide easy access to medical cannabis for qualifying patients whether it be a discount, free or some other way to help ease the finical burden a patient goes through. 

The Origin of Cannabis Compassionate Care

In California in 1996, a law was passed called Proposition 215, or the Compassionate Use Act of 1996, this allowed the use and access to the medical cannabis despite there would be no approval from the FDA (Food and Drug Administration). The act was spearheaded by a group of activists led by Dennis Peron, who was an American businessman and marijuana activist. Proposition 215 was the first medical cannabis ballot initiative that passed at the state level.  Through the help of a dedicated community of activists passionate about ensuring that everyone should have fair access and receive medical cannabis treatment, this helped pave the way for many other organizations, licensed producers, dispensaries and non-profit organizations to take initiative and provide access to patients in need of medical cannabis.
Thus known as the Cannabis Compassionate Care program.

Who is Eligible for Medical Cannabis Compassionate Care?

The programs are constantly evolving and expanding but currently there are services available to veterans, low income, and terminally ill patients. The criteria varies in each state that offers medical cannabis.  For example, Sweet Leaf is a dispensary in Colorado that formed the Sweet Leaf Collective, a donation based charity where they provide free medical cannabis locally to those that are suffering from HIV/AIDs and Cancer.  This is just one example of an organization striving to make a difference and changing lives. To date, they have provided free medical cannabis to over 150 terminally ill patients.

See what is available for compassionate care programs are available in your area.

Author Bio: Dawna Lemoine is a mom of 3 with a passion for health and wellness. After injuring her back and neck from a car accident she used natural health techniques to manage her pain and speed healing with cannabis. Her personal experiences and having previously worked in the cannabis industry has revived her passion for the herb. Her site, cannabiscuresall.net features information for people that are just starting out and starting their healing process.

Weed the People Documentary Premieres in New York to Outstanding Reviews

byMoira Feeney
Oct 29-edited
The film takes the audience into the homes of five families who decide to use MMJ to treat their children's cancer.

Filmmakers Abby Epstein and Ricki Lake spent the last six years working on the documentary, Weed the People, which looks at medical cannabis treatment for childhood cancers.  The film takes the audience into the homes and hearts of five families who decide to use medical cannabis to treat their children, in some cases alongside chemotherapy, while other parents choose to use medicinal cannabis exclusively after traditional medicine failed.  Executive director, Ricki Lake became interested in medical marijuana when her late ex-husband, Christian Evans, began researching CBD for relief from chronic pain and depression. Sadly, Evans committed suicide in 2017. 
Lake worked with award-winning director, Abby Epstein, who was Lake’s creative partner on their first award-winning documentary made in 2008, The Business of Being Born.
Weed the People looks beyond weed-activism and the politics surrounding it and takes a deep dive into the science behind medicinal cannabis through interviews with a series of authoritative physicians and researchers, including cannabis pioneer Mara Gordon, who specializes in the development of cannabis extract treatment protocols for seriously ill patients. These experts are interspersed with the compelling stories of ordinary families who are seeking the best for their children while having to face off with the US government’s backward laws on medical cannabis.
To see when Weed the People is playing in your town, check the website.  https://www.weedthepeoplemovie.com/

New Jersey Expands Medical Marijuana Program

In March 2018, NJ Governor Phil Murphy signed off on several expansions and changes to the state’s existing medical cannabis program, according to WABC, a New York TV station. These changes are expected to make getting medical marijuana in New Jersey even easier for patients and make the recommendation process painless for physicians.

More Qualifying Conditions

The program expansion added five new conditions to the list of conditions that qualify for medical marijuana.

The list now includes:

• Tourette’s Syndrome
• Anxiety
• Migraines
• Chronic Visceral Pain
• Chronic Pain Musculoskeletal Disorders

Going Beyond Dispensaries

Whereas before patients had to travel great distances to reach the nonprofit alternative treatment centers, this program expansion now allows the five main centers to open satellite retail sites and a new cultivation location to make it easier to get medical marijuana to patients throughout New Jersey.

What Are Terpenes and Why Do They Matter?

3 days
Terpenes not only determine the intensity of a cannabis high, but are essential to the medicinal properties of the plant
Terpenes Are The New Green!  Move over, THC: These lesser-known compounds are taking center stage in the conversation around cannabis

What are terpenes?

Ever burned a lavender candle to help you relax before bed? Washed your dishes with citrus-based soap? Inhaled deeply in a pine forest to clear your head? If so, you’ve already experienced the health benefits of terpenes.  Terpenes (pronounced “TER-peens”) are the aromatic oils that give plants their flavor and scent. They’re responsible for the smell of plants like basil, cinnamon, lemon—and cannabis.
Why do terpenes matter?  Research shows that terpenes in cannabis provide more than just a pungent smell—they’re the x-factor that make certain cannabis strains sedative and relaxing, and others euphoric and energizing. Historically, studies have focused on cannabinoid compounds like CBD and THC. But for connoisseurs, discussions about terpenes are replacing the age-old “indica versus sativa” debate. At Kindland, Adrienne Airhart argues terpenes are the best way to predict how a strain will affect you:  While indica and sativa are easy ways to classify weed strains, the terpene profile of a plant will really tell you what will happen to your body when you get high.Research also indicates terpenes increase the effectiveness of cannabis (studies show THC extracts containing terpenes produce effects 330% greater than THC alone).

What is the entourage effect?

Terpenes don’t simply determine the character and intensity of a cannabis high—they’re essential to the medicinal properties of the plant. Many experts say CBD and THC should be consumed in concert with terpenes and other compounds to produce maximum therapeutic results. This synergistic blend of cannabis plant compounds is called “the entourage effect.” Much like the Avengers or the Beatles, the whole group of compounds working together ends up being greater than the sum of its individual parts.

What is whole plant medicine?

Many patients report better results from using whole plant cannabis medicines than from synthetic, THC-only prescription medications. In a 2011 study, less than 2% of participants preferred synthetic THC pharmaceuticals over the natural plant. In a 1991 survey of oncologists, the majority considered smoked marijuana “more effective than the legally available oral synthetic.” Psychopharmacologist Ethan Russo argues that terpenes and the entourage effect play a key role in increasing cerebral blood flow, enhancing brain activity, killing respiratory pathogens, and supporting anti-inflammatory activity.

How do you choose a strain?

There’s a reason why cannabis aficionados call it a feast for the nose and budtenders encourage you to smell the plant material, inhaling the bouquet deeply as you would a fine wine. The aroma indicates which terpenes a strain contains, and helps users anticipate what kind of effect the strain will deliver. And while there are more than 200 different terpenes found in cannabis, these are the primary players you’ll encounter when selecting your strain.


Myrcene is the most common terpene in cannabis. Also found in bay leaves, eucalyptus, lemongrass, and mango, myrcene’s aroma is described as musky and earthy (it’s a major contributor to the skunky smell cannabis is famous for). Myrcene has a medicinal properties unique among terpenes: it increases permeability of the blood-brain barrier, which helps the effects of cannabis take place more quickly. Myrcene-rich cannabis has a sedative, calming and relaxing effect, which makes it great for anxiety, pain relief, and insomnia. (Even doctors note how myrcene-heavy strains can lead the fabled couch lock.)


Pinene’s distinct aroma is similar to pine and fir, and it’s found in many conifers, as well as in rosemary, dill, basil, and parsley. Research shows that some of the unwanted side effects of THC, such as paranoia and memory loss, may be reduced by pinene. It is anti-inflammatory and increases airflow to the lungs; users say it’s great for focus and concentration.


Limonene has a sharp citrus smell, similar to oranges, lemons and limes. It’s found in citrus fruit rinds, rosemary, juniper and peppermint. Users say limonene-high strains like Pineapple Express and Super Lemon Haze elevate mood and energy levels, and is useful in treating depression.


Found in Thai basil, cloves, cinnamon leaves, cotton, and black pepper, the scent of beta-caryophyllene is spicy, woody, and peppery. Biology fun fact: beta-caryophyllene is the only terpene that binds directly to the peripheral cannabinoid receptor CB2—all other terpenes interact with CB1 (for more on this topic, check out “The Endocannabinoid System For Dummies”). Users say beta-caryophyllene provides “body buzz,” and research shows it may be highly effective in the treatment of chronic pain.


Linalool smells similar to floral and lavender, and it’s found in lavender, citrus, laurels, birch, coriander, and rosewood. Linalool has been used for thousands of years as a sleep aid, and it’s also helpful in treating acne. Strains high in linalool like LA Confidential or Lavender Haze are BOTH relaxing and anti-inflammatory. Linalool helps users manage stress, and can also lessen the anxiety some people experience with pure THC.

Humulene is found in hops—it’s what gives beer its distinct ‘hoppy’ aroma.
Several studies have shown humulene to have anti-inflammatory properties; others have shown it to be an anti-cancer agent. (HERB sang humulene’s praises in an article entitled “The Anti-Inflammatory, Cancer Killing Terpene That Smells Like Beer.”)


Terpinolene is used widely in soaps and perfumes, and is found in apples, tea treas, lilacs, and cumin. It has a piney, smoky scent with some herbal and floral notes. Terpinolene is anti-fungal, anti-bacterial, and useful for helping insomnia and reducing anxiety. Tea tree oil and the famous Sour Diesel strain are both high in terpinolene.


Camphene is present in turpentine, camphor oil, and citronella oil. Its smell is described as pungent and damp. When mixed with Vitamin C, camphene becomes a powerful antioxidant, and studies indicate it may be able to treat cardiovascular disease.
Author bio: Jennifer Boeder is a Los Angeles-based cannabis writer. Her work has appeared in Cannabis Culture, Chicagoist, Wonkette, PUSH Mag, Built In Chicago, Gapers Block, The Urbaness, and The Tylt. You can follow her on Twitter.


What Are Terpenes and Why Do They Matter?



How To Make The Perfect Marijuana Brownies
By Johnny Green on January 23, 2012 Cooking

When making ‘marijuana edibles’, you don’t just throw the marijuana buds into the food and chow down. The THC (tetra-hydro-cannibol – the main active ingredient in marijuana) must first be extracted into a butter or oil mixture and then added or cooked with the food, especially when making marijuana brownies.

My favorite marijuana edible to make is, without a doubt, weed brownies. This article will show you how you can make weed brownies and extract the THC using butter or oil, however, most brownies recipes ask for oil instead of butter.

The Perfect Marijuana Brownie Recipes

Marijuana Brownies: OIL Method

What You Need:

Oil (any other than olive oil)

2.5 grams of weed per serving (an half ounce of dank or an ounce of mids works well for a full batch)
A Grinder
A Filter (coffee filter, pasta strainer)
Brownie mix
A Frying pan
A wood spoon
Making the Marijuana Oil

Grind up the marijuana in your grinder or a coffee grinder multiple times until it literally turns into powder.
Spread the powdered marijuana onto a frying pan. For an even cook – which is important of extracting the THC – it’s a good idea to match the frying pan to the burner size.

Pour oil directly onto the marijuana powder in the pan, according to the amount asked for in the brownie recipe.

Turn the burner on low, until until the oil and powder start to simmer.

Turn burner heat to the lowest setting. Leave the burner on for 2-6 hours depending on how much time you have (2 hrs is average). Make sure to stir the marijuana oil every 30 minutes with a wooden spoon.

When oil is done absorbing the THC, pour the oil mixture into a filter (coffee filter works fine) to strain all the excess marijuana out.

The final product should be a musky brown color oil without any grass, stems, or seeds in it.

Use this oil to make the brownies by following the instructions on the brownie box. If you prefer to make weed brownies using butter rather than oil, continue reading.

Marijuana Brownies: BUTTER Method

What You Need:

2.5 grams of weed per serving (an ounce of dank or an ounce of mids works well)
A Grinder
A Filter (coffee filter, pasta strainer)
Brownie mix
A small pot and a larger pot
A wood spoon

Fill the larger pot with clean water and place on a burner the same size as the pot for even cooking. Place the smaller pot inside the larger one.

Add 2-3 sticks of butter.

Turn the burner on a low setting until the water in the larger pots begins to simmer.

Lower temperature to a medium low setting to establish a near simmer. Make sure to keep the heater lower since the the water in the larger pot will heat up the marijuana’s THC which could destroy the THC, making the brownies useless.

Proceed to leave the the burner on for 2-3 hours, or longer.

Once done, pour the butter through a filter removing any seeds, stems, or left over marijuana bud.
 Spread this butter throughout the bottom of a large pan.

Pour the brownie mixture on top.
Cook in the oven at 250 degrees for 30 minutes to an hour.

Israel: Patient Survey Finds 90% Effectiveness Rate For Medical Marijuana Use

Posted by Johnny Green at 7:04 PM on June 5, 2016 Medical Marijuana Policy

Share on FacebookShare on TwitterShare on Google+
More and more people are using medical marijuana every day across the globe. As the stigma surrounding cannabis use continues to erode, I expect that trend to continue. Why are more and more people turning to medical marijuana? That answer is simple – it works. Consider the results of a survey out of Israel which found that medical marijuana was effective for almost every one that used it. Per The Joint Blog:

Over 90% of patients enrolled in Israel’s medical cannabis program report significant improvements in symptoms such as pain and nausea, according to a new survey presented at the Sixth International Jerusalem Conference on Health Policy.

For the survey, researchers at Ben-Gurion University surveyed demographic characteristics of patients enrolled in the nation’s medical cannabis program over a period of two years. Only six percent stated that medical cannabis was ineffective in treating their condition. Patients were most likely to report that cannabis provided relief from pain, nausea, anxiety and loss of appetite.
If someone does not want to try medical cannabis, I can live with that, provided it’s for the right reasons. I know a lot of people that could benefit from using medical cannabis, but they don’t solely because marijuana is illegal. That line of reason is something that I can’t accept. But regardless, if someone feels that medical marijuana works, and their doctor agrees, they should be able to use medical cannabis. That should be the case in America, Israel, and anywhere else where patients are suffering.


Federal Politicians Urge Obama To Remove Barriers To Research On Medical Marijuana
Posted by Johnny Green at 8:15 PM on April 18, 2016  Marijuana Science, Medical Marijuana Policy
April 18, 2016Share on FacebookShare on TwitterShare on Google+

U.S. Senator Kirsten Gillibrand (D-NY), joined by a bipartisan group of 26 Senators and Representatives, today sent a letter urging President Obama to remove barriers to research on medical marijuana and facilitate new medical research on cannabis and its derivatives.

“Twenty-three states have passed laws establishing medical cannabis programs and an additional seventeen have passed laws regarding the medical use of cannabidiol (CBD), a compound derived from cannabis,” the Senators and Representatives wrote in the letter. “Despite these developments, researchers, doctors, and patients in these forty states are still subject to federal barriers impeding innovation and medical research. Until we have comprehensive scientific research on the medical risks and benefits of cannabis and its derivatives, we will continue to debate this issue on the basis of outdated ideology instead of modern science.”

Gillibrand was joined by U.S. Senator Rand Paul (R-KY), U.S. Senator Cory Booker (D-NJ), U.S. Senator Jeff Merkley (D-OR), U.S. Senator Barbara Boxer (D-CA), U.S. Senator Patty Murray (D-WA), U.S. Senator Ron Wyden (D-OR), U.S. Senator Tammy Baldwin (D-WI), U.S. Senator Michael Bennet (D-CO), U.S. Senator Chris Murphy (D-CT), U.S. Representative Earl Blumenauer (D-OR), U.S. Representative Morgan Griffith (R-VA), U.S. Representative Steve Cohen (D-TN), U.S. Representative John Conyers (D-MI), U.S. Representative Sam Farr (D-CA), U.S Representative Raul Grijalva (D-AZ), U.S. Representative Barbara Lee (D-CA), U.S. Representative Ted Lieu (D-CA), Congresswoman Eleanor Holmes Norton (D-DC), U.S. Representative Ed Perlmutter (D-CO), U.S. Representative Mark Pocan (D-WI), U.S. Representative Jared Polis (D-CO), U.S. Representative Jan Schakowsky (D-IL), U.S. Representative Eric Swalwell (D-CA), U.S. Representative Adam Smith (D-WA), U.S. Representative Dina Titus (D-NV), and U.S. Representative Zoe Lofgren (D-CA).

The full text of the letter is included below:

The Honorable Barack Obama

President of the United States

The White House

1600 Pennsylvania Avenue

Washington, DC 20500


Dear Mr. President:

We write to request your help in removing the administrative barriers to scientific research on medical treatments derived from the cannabis plant, also known as “medical marijuana.” We have heard from numerous patients across the U.S. and parents whose children have treatment-resistant conditions about the benefits they have experienced from using cannabis to treat serious illnesses. Many prominent physicians and physician groups, including the American Medical Association, the American College of Physicians, the American Academy of Neurology, and the American Academy of Family Physicians, have joined patients and families in calling for more research about the use of medical cannabis.[i]  Twenty-three states have passed laws establishing medical cannabis programs and an additional seventeen have passed laws regarding the medical use of cannabidiol (CBD), a compound derived from cannabis.  Despite these developments, researchers, doctors, and patients in these forty states are still subject to several federal barriers impeding innovation and medical research.

While legislation has been introduced to address the legal barriers, many impediments to research could be removed with no change to existing law. To address these federal barriers, members of both houses of Congress have engaged with the Department of Health and Human Services (HHS), the Office of National Drug Control Policy (ONDCP), and the Drug Enforcement Administration (DEA) on multiple occasions through correspondence[ii], hearings[iii] and staff-level briefings. While the Administration’s most recent response from HHS Secretary Burwell, ONDCP Director Botticelli, and DEA Acting Administrator Rosenberg on April 4, 2016 provides additional context on the current system, it still offers no clear plan to remove existing barriers or stimulate new research. In 2015, only two researchers in the United States received a DEA-approved supply of cannabis for medical research in humans. At the recent National Institutes of Health (NIH) neuroscience summit on cannabinoids, multiple researchers said that the federal government’s current administrative barriers dissuade qualified scientists and doctors from even applying to research cannabis. Therefore, we ask you to take the following two actions to remove barriers and encourage medical research:

I.       Direct the DEA to Conduct a Fair and Transparent Review of Schedule I Restrictions on Medical Cannabis.
The Controlled Substances Act (CSA) of 1970 classified cannabis as a Schedule I substance, reserved for drugs with “no currently accepted medical use,” without citing any scientific evaluation of its medical use. The Schedule I status means it is more difficult to conduct medical research on cannabis than on cocaine or methamphetamines, even though almost half of all Americans live in states which have passed medical cannabis laws. The FDA’s Deputy Director for Regulatory Programs testified before Congress in June 2015 that rescheduling could “expand opportunities for research” and “send a message that it is important to do [research] and it is possible to do it.”

Rescheduling a substance from Schedule I requires establishing that one of the following conditions is true: that the substance has “accepted medical use,” that the substance has “accepted safety under medical supervision,” or that the substance does not have “high potential for abuse.”  Over the past 43 years, multiple petitions[iv] have been filed to reschedule cannabis.  The first petition was filed in 1972, and in 1988 DEA Chief Administrative Law Judge Francis recommended that it be rescheduled.  However, that recommendation was overruled by the DEA Administrator in 1989.  Subsequent petitions have been rejected, and the most recent petition, filed in 2011 by Governor Chafee of Rhode Island and Governor Gregoire of Washington, has not yet been responded to by the DEA. In a November 2015 briefing to Senate staff, representatives of the Administration refused to provide information regarding the current status of the 2011 petition. However, in September 2015, the Department of Justice had already responded to Congressman Earl Blumenauer’s inquiry regarding the petition by stating that the DEA had “received the HHS scientific and medical evaluations as well as a scheduling recommendation.” According to the April 4 letter, DEA acknowledged that the agency “hopes to release its determination in the first half of 2016.”  We welcome the announcement that the Administration has set a timeline for this determination.  Given previous issues with transparency in the scheduling process, we request that public hearings also be held to allow researchers, doctors, and patients an opportunity to inform this decision in an open, transparent manner.

II.    End the DEA-Mandated NIDA Monopoly.
Currently, the University of Mississippi, through a National Institute on Drug Abuse (NIDA) contract, possesses the only DEA license to grow cannabis for medical research in the United States.  This monopoly on a medical research supply does not exist for other Schedule I substances.  NIDA Director Dr. Nora Volkow testified before Congress in June 2015 that there is “no scientific reason” for the monopoly, that it “is not something NIDA chose to do,” and that without it, “efficiency, effectiveness, availability for research would be better.”

The DEA has previously claimed that licensing sources of cannabis for medical research outside of the NIDA drug supply program would be a violation of the 1961 Single Convention on Narcotic Drugs.  However, the State Department, other signatories to the Single Convention, and even DEA’s own Administrative Law Judge have had less rigid interpretations of the treaty.  In October 2014, the State Department, which is responsible for interpreting treaties for the U.S. government, announced a new “flexible interpretation” policy toward the Single Convention.[v] Meanwhile, countries such as Canada, Israel, and the U.K. have implemented programs that adhere to the Single Convention while allowing licensed businesses to cultivate and distribute cannabis for medical purposes. For example, Health Canada currently has 30 licensed producers of medical cannabis. In a 2007 ruling, DEA Administrative Law Judge Mary Ellen Bitner recommended granting an additional license to supply cannabis for medical research, saying that this supply would fall under the “medicinal” exception to the Single Convention and “therefore the government monopoly would not apply.”  But, the Deputy Administrator overruled Judge Bitner’s recommendation in 2009.

Among its justifications for refusing to grant additional licenses, the DEA has cited that cannabis has “no currently accepted medical use,”[vi] as indicated by the drug’s Schedule I status. However, researchers will never be able to demonstrate “accepted medical use” to DEA standards[vii] without a sufficient drug supply, hence creating a chicken-and-egg scenario.  DEA-licensed researchers have told us that this monopoly is the most significant barrier to research, because the NIDA drug supply program is inadequate to conduct the basic research that physicians and patients need to better inform their decisions and the clinical trials necessary for medical research, including drug development.

We have repeatedly asked the DEA why it is not following the precedent set by other countries and how it plans to work within the Single Convention to utilize the already existing supply of cannabis being cultivated in states that have passed legislation regarding its medical use. HHS, DEA and ONDCP have stated, “We do not have sufficient information regarding the cultivation of cannabis in these other nations” and production in the United States is not permitted “outside the system of controls described under the treaty.”  These statements do not provide a rationale for the DEA’s narrow interpretation of the Single Convention, nor address the issue of an inadequate supply for medical research.  We request that you direct the DEA Administrator to eliminate this barrier to research and grant additional licenses outside of the NIDA drug supply program to provide a supply of cannabis which is adequate to do medical research, up to the standards required by the DEA to prove “accepted medical use.”

Together, these two actions will encourage innovation and facilitate new medical research. As states have attempted to expand access to medical treatments for their citizens, the federal government has a responsibility to act in a manner that allows patients to benefit from research on those treatments.  Until we have comprehensive scientific research on the medical risks and benefits of cannabis and its derivatives, we will continue to debate this issue on the basis of outdated ideology instead of modern science.  We look forward to hearing from you on this matter.

Source: Senator Kristen Gillibrand press release

BREAKING NEWS: US Gov’t Admits Cannabis Cures Cancer

Posted by Nurse Mary-Jane on 02/05/2016 in Medical Marijuana

Location: United States | Source: National Cancer Institute

It's time to reschedule cannabis

The moment medical marijuana has been waiting for since California first passed laws legalizing the medicinal use of cannabis, in 1996, is finally here — the US government has, at last, admitted that marijuana has medical benefit. Yes, you heard right  the US government recently updated content pages on the National Cancer Institute’s (an official division of the US Department of Health) website to include information about, cannabis and cannabinoids. 

Attempting to not draw too much attention to the update, the US National Cancer Institute quietly updated their website in January, admitting that cannabis and cannabinoids kill cancer without damaging the body’s normal cells. Considering that cannabis is a Schedule 1 drug, which according to the Controlled Substances Act of 1970, means that it holds NO MEDICINAL VALUE, how could such a unbelievable admission go unnoticed by mainstream media? After all this is the plant that has been demonized as the “gateway drug”, for the past 80 years — this is BREAKING NEWS!!

The pages include a section for both patients, and physicians, and covers topics ranging from the medical effects of cannabinoids, to preclinical studies conducted using cannabis or cannabinoids. Studies in mice and rats have shown that cannabinoids may inhibit the growth of a tumor by causing cell death, blocking cell growth, and blocking the development of blood vessels need by tumors to grow. While further animal and laboratory study’s have shown evidence that cannabinoids may be able to kill cancer cells while protecting normal cells.

Additional studies have shown that there is evidence of cannabinoids protecting against inflammation and cancer of the colon; may have anti-tumor effects; may be effective in stoping breast cancer; and may make chemotherapy more effective.

Also included, is commentary about how the US government distributed cannabis to patients on a case-by-case basis under the Compassionate Use Investigational Drug (IND) program between 1978 and 1992, despite while claiming that cannabis held no medicinal value. It goes on further to say that researchers, have studied how cannabinoids act on the brain and other parts of the body, and have discovered cannabinoid receptors (molecules that bind cannabinoids) in both brain cells, and nerve cells in other parts of the body, with further evidence of cannabinoid receptors on immune system cells, suggesting that cannabinoids may play a key role in immunity, too.

It also includes information on its effectiveness to stimulate an appetite, relieve pain, reduce inflammation, control nausea and vomiting, it’s anti-anxiety effects.

Since the early 1990’s physicians have been prescribing opioid medications at an ever-increasing, and alarming rate. Resulting in an epidemic far greater in evil, than any reefer madness. The US, is now battling to counter the out-of-control, critical state of prescription drug abuse that is plaguing all classes, ethnicities, and ages. It is estimated that 52 million people have used prescription pills for non-medical reasons at least once in their lifetime, including a overwhelming large number of young people. The National Institute on Drug Abuse (NIDA) conducted a survey called “Monitoring the Future”, which found that 1 in 12 high school seniors reported non-medical use and abuse of prescription pills, while rating Vicodin, and OxyContin, as the most commonly abused drugs by adolescents. In an effort to regain control of the pill-popping monster that has been pharmaceutically created, the US is clamping down on the physicians who have writing the prescriptions, enforcing a strict new protocol that is leaving only pain management physicians with the right to prescribe pain pills. 

Which leaves us to wonder only one thing - could the federal government be getting ready to reschedule cannabis, allowing for the medical research and scientific study of pot? 
Firstly as a solution, to curbing the pandemic of prescription abuse among people, and patients. Secondly as a peace offering, to the pharmaceutical super-giants grotesquely over-capitalizing on the current state of the nation — cannabis will open the door to a whole new pharmaceutical industry as compensation, and while this is not something we condone, the simple fact alone is enough to have the ensure that pharmaceutical lobbyists share our agenda. Thirdly, because President Obama promised to support and sign the CARERS ACT, legalizing the medicinal use of marijuana thereby allowing for its use by the Veterans Affairs, and the vets who repeatedly keep pleading for reform — Question: Why are our vets pleading? They are our veterans, the men and women who have risked their lives, to defend and protect ours. They shouldn’t need to ask - let alone still beg or plead! As a nation, we should respectfully give them anything they need to help ease their pain and suffering, as a result of their service. 
And finally - and most importantly of all - because President Obama promised change, and congressional reform of medical cannabis if the states led the way. Considering that when Obama took office in 2009 there were already 14 legal medical marijuana states, and now there’s 23 with more on the way, while 4 states and the District of Columbia have altogether legalized the recreational adult-use of pot, its clear that the states have held up their end. Now, its time for the president to uphold his.

"I don't think rescheduling is something that I would characterize as drastic,” said U.S. Rep. Earl Blumenauer (D-Oregon), one of the key members of Congress's cannabis reform cabal. "If we were scheduling today, marijuana would not be Schedule I — or Schedule II. In fact, it may not be scheduled at all."

"If we were scheduling from scratch and doing so based on scientific evidence, tobacco would be Schedule I. It's an addictive killer,” he added

In support of medicla marijuana and it's patients, everywhere:
PLEASE SHARE THIS BREAKING NEWS with as many people in your network, as you can. Help stop reefer maddness once and for all, and spread the word that the federal government has admitted the truth, about marijuana and its medicincal value.
Help PUSH President Obama to keep his promise and reschedule cannabis, for the greater good of us all!!

Time to reschedule marijuana

How To Make Medical Marijuana Tincture

Tinctures are perhaps the least popular way of consuming medical marijuana and perhaps the easiest.  Some long-term medical marijuana users might not even know exactly what tinctures are. Well, to clear that up, tinctures are a liquid concentration of cannabis, where the THC and cannabinoids have been leached out into alcohol. Put a few drops of this concentrated serum under your tongue, and within a few minutes you’ll be feeling the effects.

Here are the basic guidelines.


80 proof (or higher) alcohol

Medicinal marijuana of your choice

Small glass jar with a lid

Medicine bottle with eyedropper


Decide how much tincture you would like to make. A ratio of 3 grams of medicinal marijuana to 35 mL (1 fluid ounce) of alcohol is the minimum, although some people use up to 6 grams per 35 mL. Pick a moderate ratio for your first time, and see how it works for you. There are about 20-25 drops in 1 fluid ounce. An average dose calls for 3-4 drops, so you can expect 6-8 doses per ounce.

First you must place your medical marijuana on a sheet pan.  Spread it evenly and place it in a 225 degree oven for 20-30 minutes.  This process is called decarboxylation.   This creates a chemical reaction that releases carbon dioxide (CO2). This means a chemical reaction takes place in which carboxylic acids loose a carbon atom from a carbon chain, releasing the THC. Not every tincture recipe calls for this step but with the cost associated it is not worth taking the risk.  After the product cools, place it into the glass jar and add the alcohol.  Close the jar and shake it vigourously for a minute or so.  Then place it in a dark, cool cabinet.  Here is where patience is recommended.  Every recipe calls for a different time frame for how long it takes to complete.  All articles reviewed call for a different period of time ranging anywhere from 3 hours to 6 months.  However, most agree 30 days is optimal.  Just rememebr to shake the bottle daily while waiting.  After 30 days pour the mixture into a coffee filter and capture the tincture in a measuring cup.  Then bottle the tincture in medicine bottles of your choice.  Use responsibly.


 August 17, 2012

Smoking Vs. Vaporizing Cannabis

Depending on one’s experience within the realm of cannabis consumption, some may never have heard of vaporizing.

Vaporizing is a common technique for consuming marijuana, while at the same time negating many irritating respiratory toxins that exists within the grown marijuana flower and are released when smoked. Conversely, vaporizing allows one to get at all of the psychoactive ingredients available within that specific strain of marijuana , minus the combustion that ordinarily takes place during consumption.

The basic design of the average marijuana vaporizer is to allow marijuana smokers to inhale the many active Cannabinoids, while at the same time avoiding any of the harmful elements that may exist on that specific flower… although invisible to the naked eye.

While most don’t know it … There is a vast difference in the quality of smoke that one receives when they vaporize versus igniting their plant matter. When one smokes a joint, or hits their bong approximately 88% of the combusted smoke gases contain non-cannabinoid elements, most of which do not get you high and provide potential health risks.

Conversely when one uses a marijuana vaporizer the smoke/gases that they are inhaling consists of approximately 95% cannabinoids, otherwise known as the psychoactive ingredients that both calm the mind and soothe the body.


How to make Cannabis Tinctures

Posted by Jeandre Gerber on 11/23/2015 in Marijuana Recipes

Source: Zamnesia

Many years ago Cannabis Tinctures were easily available at your average herbal store as it was considered a perfectly normal way to treat different ailments. Now, with medical cannabis legal again in many states, tinctures are available again but not as popular as some other ways in using medical cannabis. Maybe it should be looked at in a different light, because tinctures can be very helpful and discreet. For a fast effect, a few drops could be placed under the tongue. If a slower effect is desired, it could be add to food. Dosage becomes easier with tincture and it has no smell that makes it safe to travel with and use as medical treatment.

Tinctures are not expensive to make and preserve well in the refrigerator. A benefit is that it has all 80 of the cannabinoids and acts rapidly.

What do you need?

Pure grain alcohol 90% or higher; blender; strainer; jar with lid; brown medicine bottle with dropper; funnel and cannabis of choice.


A good ratio is 1 gram of cannabis for 35 ml of alcohol. (Increase to the desired amount)

Grind the cannabis to a finer content, but not to a powder form

Put the cannabis in a jar and soak anything from 1 to a few days. The soaking allows the THC and CBD to be absorbed in the alcohol. (In the beginning some experimenting might be necessary until you find the correct tincture for you) Everyday shake the bottle ever so gently.

After the required time, strain the plant. A cheese cloth of coffee filter work very well. Capture the liquid and put it in the brown bottle. Store it in a cool place away from direct light, like a refrigerator or dark cupboard.

Start with a small dose first and remember that experimenting is to the order of the day here.

Results: - Similar to other ways of using medical cannabis, the tincture addresses the same medical issues with great effect.  The reaction time is quick and the effect can last a long time. 

Study: Marijuana Improves Outcomes In Opioid-Dependent Subjects Undergoing Treatment

Posted by at 7:15 AM on December 3, 2015 Marijuana Science, Medical Marijuana Policy

pre 98 bubba marijuana strainBy Paul Armentano, NORML Deputy Director

Cannabis use is associated with improved outcomes in opioid-dependent subjects undergoing outpatient treatment, according to data published online ahead of print in the journal Drug and Alcohol Dependence.

Researchers at Columbia University assessed the use of cannabinoids versus placebo in opioid-dependent subjects undergoing in-patient detoxification and outpatient treatment with naltrexone, an opiate receptor antagonist. Investigators reported that the administration of oral THC (dronabinol) during the detoxification process lowered the severity of subjects’ withdrawal symptoms compared to placebo, but that these effects did not persist over the entire course of treatment. By contrast, patients who consumed herbal cannabis during the outpatient treatment phase were more readily able to sleep, were less anxious, and were more likely to complete their treatment as compared to those subjects who did not.

“One of the interesting study findings was the observed beneficial effect of marijuana smoking on treatment retention,” authors concluded. “Participants who smoked marijuana had less difficulty with sleep and anxiety and were more likely to remain in treatment as compared to those who were not using marijuana, regardless of whether they were taking dronabinol or placebo.”

The findings replicate those of two prior studies, one from 2001 and another from 2009, reporting greater treatment adherence among subjects who consumed cannabis intermittently during outpatient therapy.

Population data from states where medicinal cannabis is permitted report lower rates of opioid-abuse and mortality as compared to those states where the plant is prohibited. Clinical data and case reports also indicate that the adjunctive use of cannabis may wean patients from opiates while successfully managing their pain. Survey data of state qualified medical cannabis patients demonstrates that subjects with access to the plant often substitute it for opioids because they perceive it to possess fewer adverse side effects.

Overdose deaths involving opioids have increased dramatically in recent years. While fewer than 4,100 opiate-induced fatalities were reported for the year 1999, by 2010 this figure rose to over 16,600 according to an analysis by the US Centers for Disease Control.

An abstract of the study, “The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone,” appears online here.


What Is At Stake In The War On Marijuana?

 Posted by at 6:55 AM on October 30, 2015  Marijuana Video
 October 30, 2015

The Brookings Institution has put out some literature lately dealing with marijuana, the most recent of which calls for removing barriers to marijuana research. This is something that activists have been wanting for decades, but the federal government has done everything it can to stifle progress. With organizations like the Brookings Institution calling for the removal of barriers to research, I think it’s symbolic of just how far reform has come.

The Brookings Institution released a video this week that deals with the war on marijuana, and highlights some of the issues it causes. In this video, Fellow of the Brookings Institution Dr. John Hudak PhD. explains the fall0ut that is occurring due to the war on marijuana, covering such areas as taxation and research. One part that I like about the video is that Dr. Hudak explains the two processes it would take to reschedule marijuana, either via the White House, or via Congress. As you will see in the video, an act of Congress would be much simpler in some way than Executive action, but that also would require getting a majority of hundreds of federal politicians to get off their butts, which is obviously harder in a lot of ways.

This video is timely because Bernie Sanders just announced that he plans to introduce a bill into Congress that would de-schedule marijuana entirely, effectively ending marijuana prohibition at the federal level. Below is the video, happy Friday to all, and enjoy!